Coherus Biosciences Inc (NASDAQ:CHRS)’s traded shares stood at 1.26 million during the last session, with the company’s beta value hitting 0.53. At the close of trading, the stock’s price was $2.15. The CHRS share’s 52-week high remains $8.65, putting it -302.33% down since that peak but still an impressive 33.49% since price per share fell to its 52-week low of $1.43. The company has a valuation of $239.42M, with an average of 3.39 million shares over the past 3 months.
Coherus Biosciences Inc (NASDAQ:CHRS) trade information
Coherus Biosciences Inc (CHRS) has traded red over the past five days. The stock hit a weekly high of 2.52. The 5-day price performance for the stock is -12.24%, and -3.15% over 30 days. With these gigs, the year-to-date price performance is -35.44%.
Coherus Biosciences Inc (CHRS) estimates and forecasts
Looking at statistics comparing Coherus Biosciences Inc share performance against respective industry, we note that the company has outperformed competitors. Coherus Biosciences Inc (CHRS) shares are -44.16% down over the last 6 months, with its year-to-date growth rate higher than industry average at 100.51% against 12.80%. Revenue is forecast to grow 68.00% this quarter before jumping 42.10% for the next one. The rating firms project that company’s revenue will grow 1.70% compared to the previous financial year.
Revenue forecast for the current quarter as set by 5 analysts is $81.7 million. Meanwhile, for the quarter ending Jun 2024, a total of 5 analyst(s) estimate revenue growth to $53.68 million.Earnings reports from the last fiscal year show that sales brought in $47.44 million and -$ respectively in the corresponding quarters.
CHRS Dividends
Coherus Biosciences Inc has its next earnings report out in May. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Coherus Biosciences Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
